Mineralys Therapeutics, Inc. Common Stock (MLYS) Stock Forecast & Price Target
Mineralys Therapeutics, Inc. Common Stock · NASDAQ
$26.93-0.28 (-1.03%)
15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 7 firms covering Mineralys Therapeutics, Inc. Common Stock, 6 rate it Buy or better, 1 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets range widely, $26.00 to $56.00 (about 2.2x), a sign of real disagreement on valuation. The average target of $48.67 sits 81% above the current $26.93. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.56 next quarter toward $-2.10 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS7 ratings
Strong Buy
Strong Buy00%
Buy686%
Hold114%
Sell00%
Strong Sell00%
Based on 7 analysts giving stock ratings to Mineralys Therapeutics, Inc. Common Stock.
As of Jul, 6 of 7 firms rate MLYS a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
MLYS EPS & revenue forecast
EPS · NEXT QUARTER
$-0.56
Range $-0.63 – $-0.41 · 8 analysts · +8% YoY
Next period, 8 analysts expect Mineralys Therapeutics, Inc. Common Stock to earn $-0.56 a share (range $-0.63 – $-0.41), versus $-0.52 a year earlier. Full-year consensus is $-2.24, growing to $-2.10 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 8 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $121.4M next year.
Top analysts covering Mineralys Therapeutics, Inc. Common Stock
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on MLYS.
#1
MC
Matthew Caufield
HC Wainwright & Co. · Rank #51
Buy
$56.00+107.9% to target
Overall win rate
56%
+ Follow
#2
Jason Gerberry
B of A Securities · Rank #136
Buy
No targeton MLYS
Overall win rate
46%
+ Follow
#3
Mohit Bansal
Wells Fargo
Buy
$55.00+104.2% to target
Coverage
—
+ Follow
#4
DD
Dennis Ding
Jefferies
Hold
$26.00-3.5% to target
Coverage
—
+ Follow
#5
Annabel Samimy
Stifel
Buy
$52.00+93.1% to target
Coverage
—
+ Follow
MLYS stock forecast FAQ
What is MLYS's average 12-month price target?+
The 6 analysts with a live target average $48.67 for Mineralys Therapeutics, Inc. Common Stock over the next 12 months, ranging from a $56.00 high to a $26.00 low.
Is MLYS stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 7 analyst ratings, 6 are Buy or Strong Buy, 1 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for MLYS?+
The Street-high target is $56.00 (HC Wainwright & Co.), and the Street-low is $26.00 (Jefferies). The average of all 6 active targets is $48.67.
How many Wall Street analysts cover MLYS?+
7 analysts have an active rating on Mineralys Therapeutics, Inc. Common Stock, and 6 firms carry a live 12-month price target.
Who is the most accurate analyst covering MLYS?+
Among analysts who currently cover MLYS, Matthew Caufield of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #51). Their current call is Buy with a $56.00 target.
What is Mineralys Therapeutics, Inc. Common Stock's projected EPS for next quarter?+
The consensus estimate is $-0.56 per share (range $-0.63 – $-0.41) across 8 analysts. Full-year EPS is projected at $-2.24, rising to $-2.10 the following year.
How much revenue is Mineralys Therapeutics, Inc. Common Stock expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $121.4M next year.
Have analysts been upgrading or downgrading MLYS lately?+
As of Jul, 6 of 7 firms rate MLYS a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their MLYS calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
